Li AM, Hucks GE, Dinofia AM, et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. ASH Annual Meeting and Exposition 2018, abstract 556.
Apixaban niet inferieur aan dalteparine bij kankergeassocieerde VTE
jun 2020 | Benigne hematologie